; and (B) by adding at the end the following: (2) Limitation The total value of awards provided by a Federal agency under this subsection in a fiscal year shall be— (A) except as provided in subparagraph (B), not more than 10 percent of the total funds allocated to the SBIR and STTR programs of the Federal agency during that fiscal year; and (B) with respect to the National Institutes of Health, not more than 15 percent of the total funds allocated to the SBIR and STTR programs of the National Institutes of Health during that fiscal year. (3) Extension During fiscal year 2025, each Federal agency with an SBIR or STTR program may continue phase flexibility as described in this subsection only if the reports required under subsection (tt)(1) have been submitted to the appropriate committees. ; (4) in subsection (hh)(2)(A)(i), by striking simplified and standardized procedures and model contracts and inserting a simplified and standardized application process and requirements, procedures, and model contracts ; and (5) by adding at the end the following: (yy) Technology Commercialization Official Each Federal agency participating in the SBIR or STTR program shall designate a Technology Commercialization Official in the Federal agency, who shall— (1) have sufficient commercialization experience; (2) provide assistance to SBIR and STTR program awardees in commercializing and transitioning technologies; (3) identify SBIR and STTR program technologies with sufficient technology and commercialization readiness to advance to Phase III awards or other non-SBIR or STTR program contracts; (4) coordinate with the Technology Commercialization Officials of other Federal agencies to identify additional markets and commercialization pathways for promising SBIR and STTR program technologies